EU Case Reports
Journal of Generic Medicines (2007) 4, 133–141. doi:10.1057/palgrave.jgm.4950057; published online 19 December 2006
Preliminary injunctions, regulatory approvals and parallel imports
Compiled and written by Olswang
Olswang is a UK technology law firm providing a comprehensive range of commercial legal services for companies in the pharmaceutical, biotechnology and medical device sectors.
Corporate
Private equity/VC
Public funding/IPO
UK/EU establishment
Banking and finance
Tax
Employment/labour law
Share schemes/employee incentive schemes
Competition/antitrust/regulatory
Intellectual property
Patent, design and trademark filing and prosecution (UK and EU)
Commercial exploitation and collaboration (eg R&D, MTA, NDA, CRADA, JV)
Strategic IP portfolio and advice and management
Freedom to operate/risk analysis opinions
Litigation (UK and EU)
This section summarises and comments on recent interesting judgements. It is not intended to be
exhaustive, nor are the papers intended to constitute legal advice. For further information contact:
Michael Burdon
Partner and Head of Biosciences Group
Olswang
90 High Holborn
London WC1V 6XX
UK
Tel: +44 (0) 20 7067 3279
Fax: +44 (0) 20 7067 3999
Email: Michael.burdon@olswang.com
Web: www.olswang.com
Michael Burdon1, Priya Vatvani2 and Oliver Ellington3
1is a partner and Head of the Biosciences Group at Olswang.
2is a barrister at Olswang.
3is a trainee solicitor at Olswang.
MORE ARTICLES LIKE THIS
These links to content published by Palgrave Macmillan are automatically generated.
RESEARCH
Preliminary injunctions, regulatory approvals and parallel importsJournal of Generic Medicines Case Report
EU Legal and Regulatory UpdateJournal of Generic Medicines EU Legal and Regulatory Update
TrademarkJournal of Generic Medicines EU Legal and Regulatory Update
Abbott v Torpharm: The Contours of ContemptJournal of Generic Medicines Case Report
EU Legal and Regulatory UpdateJournal of Generic Medicines EU Legal and Regulatory Update
See all 8 matches for Research


